ABSTRACT

Background: Pulmonary hypertension (PH) is common in patients with idiopathic pulmonary fibrosis (IPF) and is associated with poor outcomes. This study was performed to determine the clinical efficacy of PH-specific therapeutic agents for IPF patients.

Methods: We performed a systematic review and meta-analysis using MEDLINE, EMBASE, and the Cochrane Central Register. We searched randomized controlled trials (RCTs) without language restriction until November 2018. The primary outcome was all-cause mortality to end of study.

Results: We analyzed 10 RCTs involving 2,124 patients, 1,274 of whom received PH-specific agents. In pooled estimates, the use of PH-specific agents was not significantly associated with reduced all-cause mortality to end of study compared with controls (hazard ratio, 0.99; 95% confidence interval [CI], 0.92, 1.06; \( P = 0.71; I^2 = 30\% \)). When we performed subgroup analyses according to the type of PH-specific agent, sample size, age, forced vital capacity, diffusion lung capacity, and the extent of honeycombing, PH-specific agents also showed no significant association with a reduction in all-cause mortality. A small but significant improvement in quality of life, measured using the St. George Respiratory Questionnaire total score, was found in the PH-specific agent group (mean difference, −3.16 points; 95% CI, −5.34, −0.97; \( P = 0.005; I^2 = 0\% \)). We found no significant changes from baseline in lung function, dyspnea, or exercise capacity. Serious adverse events were similar between the two groups.

Conclusion: Although PH-specific agents provided small health-related quality-of-life benefits, our meta-analysis provides insufficient evidence to support their use in IPF patients.

Keywords: Idiopathic Pulmonary Fibrosis; Hypertension, Pulmonary; Vasodilator Agents; Treatment Outcome

INTRODUCTION

Idiopathic pulmonary fibrosis (IPF) is a specific form of progressive, irreversible, and fatal fibrosing interstitial pneumonia of unknown etiology.\(^1\) Although two antifibrotic agents,
nintedanib and pirfenidone, are available to reduce disease progression in patients with mild to moderate IPF, randomized controlled trials (RCTs) have not demonstrated significant improvement in the IPF mortality rate or acute exacerbations, indicating a need for novel or additional agents to treat IPF.

Pulmonary hypertension (PH) is common in IPF patients. The presence of PH in IPF, as measured by Doppler echocardiography, ranges widely from 32% to 85%, depending on the disease severity, evaluation method, and diagnostic criteria. Furthermore, PH has been observed in approximately 20% of patients with mild to moderate restricted IPF and in 28.8%–46.1% of patients with end-stage IPF awaiting lung transplantation, as measured by right heart catheterization. The presence of PH is correlated with mortality, impaired gas exchange, and reduced exercise capacity in IPF patients, and it has been well established that the development of PH plays an important role in IPF prognosis. Thus, active intervention for IPF-associated PH might improve long-term outcomes, and it could be plausible to consider PH-specific agents as a therapeutic option for IPF patients.

Current international guidelines for the diagnosis and management of IPF do not recommend PH-specific agents for the majority of IPF patients. However, several previously published trials have reported that they offer clinical benefits for exercise capacity, symptoms, and quality of life. Considering the contradictory results published about PH-specific agents, we conducted a systematic review and meta-analysis to evaluate the clinical efficacy and safety of PH-specific agents for IPF patients.

**METHODS**

**Data sources and search strategy**

We performed electronic literature searches of MEDLINE, EMBASE, and the Cochrane Central Register using search filters provided by SIGN (http://www.sign.ac.uk/methodology/filters.html) and following the recommended guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses. Searches were limited to human studies without language restriction through November 2018. As search terms, we used the following keywords: “idiopathic pulmonary fibrosis” or “fibrosing alveolitis” or “usual interstitial pneumonia” AND “endothelin receptor antagonist” or “prostacyclin” or “prostacyclin derivative” or “phosphodiesterase-5 inhibitor” or “soluble guanylate cyclase stimulators” or “bosentan” or “ambrisentan” or “sitaxentan” or “macitentan” or “sildenafil” or “tadalafil” or “ udenafil” or “vardenafil” or “riociguat” or “epoprostenol” or “treprostinil” or “beraprost” or “iloprost.” We also performed a manual search of the references cited in relevant review articles.

**Study selection and data extraction**

The following predetermined inclusion criteria were used: 1) full-length reports published in peer-reviewed journals; 2) RCTs comparing PH-specific agents with controls; 3) active interventions for one of the four PH-specific agent classes: endothelin receptor antagonists (ERAs), prostacyclin or prostacyclin analogues, soluble guanylate cyclase stimulators (sGCs), or phosphodiesterase type 5 (PDE5) inhibitors; 4) patients diagnosed with IPF according to international consensus guidelines; and 5) clinical outcomes and adverse events data available.
Two investigators independently retrieved potentially relevant studies, reviewed each study according to the predefined eligibility criteria, and extracted data. Disagreements were resolved through discussion between them. For each study, a predesigned form was used to extract data on the authors, publication year, population, interventions, controls, clinical outcomes, and adverse events. We excluded case reports, case series, letters to the editor, editorials, and commentaries because the methods and results could not be fully analyzed. The primary outcome of interest was all-cause mortality to end of study, defined as the time from random assignment to death from any cause. Secondary outcomes were forced vital capacity (FVC), diffusion capacity of the lung for carbon monoxide (DLco), 6-minute walk distance test (6MWD), St. George Respiratory Questionnaire (SGRQ) total score, Borg dyspnea score after walk test, and serious adverse events related to treatment.

**Risk of bias assessment**

The quality of the RCTs was assessed using the Cochrane Handbook for Systematic Reviews of Interventions’ risk of bias tool. This scale evaluates the following criteria: sequence generation/allocation concealment (selection bias), blinding of participants and personnel (performance bias), blinding of outcome assessment (detection bias), incomplete outcome data (attrition bias), selective outcome reporting (reporting bias), and other sources of bias. Risk of bias was labeled as high, low, or unclear. Reviewer agreement was achieved through consensus. If any randomized or blinded item was judged as high risk, the trial was assigned a high risk of bias. The publication bias was assessed using Begg’s and Egger’s regression tests.

**Data synthesis and statistical analysis**

Summary measures of risk ratios (RRs) or hazard ratios (HRs) were calculated as appropriate with 95% confidence intervals (CIs) to assess the treatment efficacy of PH-specific agents. Statistical heterogeneity was assessed by calculating $I^2$ values to quantify the degree of heterogeneity between studies on a scale of 0%–100%. We considered a value of $I^2$ between 30% and 60% as an indication of moderate heterogeneity and > 60% as significant between-study heterogeneity. If substantial heterogeneity existed, a random effect model was used for the analysis; otherwise, a fixed effect model was used. We also conducted sensitivity analyses using the leave-one-out method to evaluate the influence of highly heterogeneous individual studies on the overall effect estimate. Subgroup analyses for the primary outcome of interest were planned based on the type of PH-specific agent, sample size, age, FVC, DLco, and the extent of honeycombing.

A $P$ value < 0.05 was considered statistically significant. We analyzed data using Review Manager Software, version 5.3 (The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen, Denmark) and Stata version 14.2 (StataCorp LP, College Station, TX, USA).

**Ethics statement**

Because this study was a systematic review of published articles, neither informed consent nor ethical approval was required.

**RESULTS**

**Study search, characteristics of included studies, and study quality**

The electronic database search yielded 579 published articles (Fig. 1). After removal of duplicate articles, the titles and abstracts of 488 references were screened. Of these, 43 eligible articles were selected. After the full-text review, 10 studies reported at least one primary or secondary
outcome that could be combined in this meta-analysis. Individual characteristics of the selected studies are shown in Table 1. All included articles were published between 2008 and 2018. The number of patients in the trials ranged from 24 to 616. The active interventions were ERAs in six trials (bosentan in four, ambrisentan in one, and macitentan in one) and a PDE5 inhibitor in four trials (sildenafil in all). One study included idiopathic fibrotic nonspecific interstitial pneumonia as well as IPF, and another study included results from a combined therapy of nintedanib and sildenafil. The results from the quality assessment of the included studies are shown in Table 2. One trial was judged to be at high risk of bias because it did not blind participants and researchers, nor did it blind the outcome assessment.

**Overall survival**

A forest plot of the primary outcome—effects of PH-specific agents on all-cause mortality at the study endpoints—is shown in Fig. 2. Data regarding the effects of PH-specific agents on all-cause mortality to end of study in IPF patients were available for eight trials, and we analyzed them using an inverse variation method. Of a total of 1,941 enrolled patients, 1,189 were treated with PH-specific agents, and 752 received placebo or no treatment. In pooled estimates, all-cause mortality to end of study did not differ significantly between the PH-specific agent group and the control group (HR, 0.99; 95% CI, 0.92, 1.06; \( P = 0.71 \)) (Fig. 2). There was a moderate degree of statistical heterogeneity among the eight trials (\( I^2 = 30\% \); \( P = 0.19 \)). To investigate the effect of each individual study on the overall estimates, we performed a sensitivity analysis by calculating the pooled HRs while successively excluding one study at a time. One study had a significantly different all-cause mortality estimate than the others. Even after excluding that study, however, all-cause mortality did not differ significantly between the groups, although the heterogeneity decreased (HR, 0.99; 95% CI, 0.92, 1.06; \( P = 0.78 \); \( I^2 = 0\% \)). We found no evidence of publication bias using Begg’s \( (P = 0.266) \) and Egger’s \( (P = 0.516) \) tests.
Because the result for the primary outcome was not significant, we performed subgroup analysis. When the analysis was restricted to patients treated with ERAs or PDE-5 inhibitors, all-cause mortality to end of study did not differ significantly between the groups (HR, 1.09; 95%
CI, 0.63, 1.86; P = 0.77; I² = 56% for ERAs and HR, 0.98; 95% CI, 0.92, 1.06; P = 0.67; I² = 0% for the PDE-5 inhibitor (Fig. 2). Also, all-cause mortality to end of study did not differ significantly by sample size (≥ 200 vs. < 200), age (≥ 65 vs. 65), mean FVC (≥ 60% vs. 60%), mean DLco (≥ 30% vs. < 30%), or the extent of honeycombing (definite vs. minimal or none) (Table 3).

Lung function

Seven RCTs reported data on changes in FVC from baseline,24,25,27-31 and it did not differ significantly between the PH-specific agent group and the control group (mean difference [MD], 0.69% predicted; 95% CI, −0.36, 1.74; P = 0.20; I² = 0% for FVC % predicted and MD).

Table 3. Subgroup analysis of the randomized controlled trials included in the meta-analysis

| Variables        | No. of studies | No. of patients | HR (95% CI) | I², % | P value |
|------------------|----------------|-----------------|-------------|-------|---------|
| Sample size      |                |                 |             |       |         |
| ≥ 200            | 5              | 561             | 0.99        | 0.92, 1.06 | 0.631 |
| < 200            | 3              | 1,382           | 1.03        | 0.51, 2.07 | 0      |
| Age, yr          |                |                 |             |       |         |
| ≥ 65             | 5              | 1,149           | 0.82        | 0.52, 1.30 | 0.728 |
| < 65             | 2              | 794             | 0.99        | 0.92, 1.07 | 0      |
| FVC, %           |                |                 |             |       |         |
| ≥ 60             | 5              | 1,584           | 0.99        | 0.92, 1.06 | 0.167 |
| < 60             | 3              | 359             | 0.99        | 0.46, 2.11 | 0      |
| DLco, %          |                |                 |             |       |         |
| ≥ 30             | 3              | 1,286           | 1.42        | 0.80, 2.52 | 0.268 |
| < 30             | 5              | 657             | 0.98        | 0.91, 1.05 | 0      |
| Honeycombing     |                |                 |             |       |         |
| Definite         | 6              | 835             | 0.99        | 0.92, 1.06 | 0.488 |
| Minimal or none  | 2              | 1,108           | 0.98        | 0.41, 2.37 | 0      |

HR = hazard ratio, CI = confidence interval, DLco = diffusion capacity of the lung for carbon monoxide, FVC = forced vital capacity.
0.06 L; 95% CI, −0.11, 0.24; \( P = 0.48 \); \( F = 0\% \) for FVC L) (Fig. 3A and B). Data regarding DLco changes from baseline were also available for seven trials and were analyzed using the generic inverse variation method.\(^{24,25,27-31}\) The decline in percent-predicted DLco was not significantly lower in the PH-specific agent group than in the control group (MD, 0.81%; 95% CI, −0.24, 1.87; \( P = 0.13 \); \( F = 0\% \)) (Fig. 3C). The mean change from baseline in DLco (mmol-kPa⁻¹-min⁻¹) did not differ significantly between the two groups either (MD, 0.12 mmol-kPa⁻¹-min⁻¹; 95% CI, −0.18, 0.43; \( P = 0.43 \); \( F = 0\% \)) (Fig. 3D).

Fig. 3. Pooled effects of PH-specific agents versus controls on changes of lung function; (A) FVC % predicted, (B) FVC L, (C) DLco %, and (D) DLco mmol-kPa⁻¹-min⁻¹. DLco = diffusion capacity of the lung for carbon monoxide, FVC = forced vital capacity, PH = pulmonary hypertension, MD = mean difference, SD = standard deviation, CI = confidence interval.
Quality of life, exercise capacity, and serious adverse effects

Fig. 4A shows the effectiveness of PH-specific agents in improving the quality of life for IPF patients, measured using the SGRQ total score; these data were reported in three trials. The pooled estimates show a significant improvement in the SGRQ total score in the PH-specific agent group compared with controls (MD, −3.16 points; 95% CI, −5.34, −0.97; P = 0.005; I² = 0%).

A

| Study or subgroup | PH-specific agents | Control | Weight | MD IV, Fixed, 95% CI | MD IV, Fixed, 95% CI |
|-------------------|--------------------|---------|--------|----------------------|---------------------|
| King et al.⁴⁴     | −0.70 27.95 71     | 2.60 28.84 83 | 5.9%   | −3.30 (−12.29, 5.69) |                     |
| Kolb et al.⁵⁶     | 0.23 12.01 109    | 2.42 11.89 105 | 46.6%  | −2.19 (−5.39, 1.01)  |                     |
| Zisman et al.⁶⁰   | −1.64 10.78 89    | 2.45 10.95 91  | 47.5%  | −4.09 (−7.26, −0.92) |                     |
| Total (95% CI)    |                    | 269 279 100.0% |        | −3.16 (−5.34, −0.97) |                     |

Heterogeneity: χ² = 0.68, df = 2 (P = 0.71); I² = 0%
Test for overall effect: Z = 2.83 (P = 0.005)

B

| Study or subgroup | PH-specific agents | Control | Weight | MD IV, Random, 95% CI | MD IV, Random, 95% CI |
|-------------------|--------------------|---------|--------|-----------------------|-----------------------|
| Jackson et al.⁷⁸  | 0.70 2.19 14       | −0.50 2.25 15 | 36.7%  | 1.20 (−0.42, 2.82)    |                      |
| Zisman et al.⁶⁰   | 0.04 1.61 89       | 0.37 1.58 91  | 63.3%  | −0.33 (−0.80, 0.14)   |                      |
| Total (95% CI)    |                    | 103 106 100.0% |        | 0.23 (−1.21, 1.68)    |                      |

Heterogeneity: χ² = 0.80, df = 1 (P = 0.07); I² = 69%
Test for overall effect: Z = 0.31 (P = 0.75)

C

| Study or subgroup | PH-specific agents | Control | Weight | MD IV, Fixed, 95% CI | MD IV, Fixed, 95% CI |
|-------------------|--------------------|---------|--------|----------------------|---------------------|
| Corte et al.⁴⁴    | −25.9 56.70 25     | −53.3 66.90 14 | 2.0%   | 27.20 (−14.30, 68.70) |                     |
| King et al.⁴⁴     | −52.0 121.00 71    | −34.0 127.00 83 | 2.2%   | −18.00 (−57.23, 21.23) |                     |
| Raghu et al.⁵⁵    | −11.7 33.19 329    | −9.3 31.03 163 | 95.8%  | −2.40 (−8.36, 3.56)   |                     |
| Total (95% CI)    |                    | 425 260 100.0% |        | −2.16 (−8.00, 3.68)   |                     |

Heterogeneity: χ² = 2.56, df = 2 (P = 0.28); I² = 22%
Test for overall effect: Z = 0.73 (P = 0.47)

D

| Study or subgroup | PH-specific agents | Control | Weight | RR M-H, Fixed, 95% CI | RR M-H, Fixed, 95% CI |
|-------------------|--------------------|---------|--------|-----------------------|-----------------------|
| Corte et al.⁴⁴    | 18 40              | 10 20   | 6.6%   | 0.90 (0.52, 1.57)     |                      |
| King et al.⁴⁴     | 129 407            | 74 209  | 48.0%  | 0.90 (0.71, 1.13)     |                      |
| Kolb et al.⁵⁶     | 37 137             | 44 136  | 21.7%  | 0.83 (0.58, 1.21)     |                      |
| Raghu et al.⁵⁵    | 73 329             | 25 163  | 16.4%  | 1.45 (0.96, 2.19)     |                      |
| Zisman et al.⁶⁰   | 13 89              | 15 91   | 7.3%   | 0.89 (0.45, 1.75)     |                      |
| Total (95% CI)    |                    | 1,002 619 100.0% |        | 0.97 (0.82, 1.15)     |                      |
| Total events      |                    | 270 168 |        |                       |                      |

Heterogeneity: χ² = 4.84, df = 4 (P = 0.30); I² = 17%
Test for overall effect: Z = −0.33 (P = 0.74)

Fig. 4. Pooled effects of PH-specific agents versus controls on changes in clinical parameters and for incidence of serious adverse events: (A) St. George’s Respiratory Questionnaire score, (B) Borg dyspnea score after walk test, (C) 6-minute walk distance, and (D) incidence of serious adverse events. A serious adverse event was defined as an event that resulted in death, was life-threatening, resulted in hospitalization or prolongation of hospitalization, resulted in persistent or clinically significant disability or incapacity, was a congenital anomaly or birth defect, or was deemed to be serious for any other reason. PH = pulmonary hypertension, MD = mean difference, SD = standard deviation, CI = confidence interval.
However, two RCTs reported data from the Borg dyspnea index score after walk test, and there was no difference between the two groups (MD, 0.23 points; 95% CI, −1.21, 1.68; \( P = 0.75 \)) (Fig. 4B).\(^{30,31}\) Between-trial heterogeneity was substantial (\( I^2 = 69% \)). Three trials evaluated the effectiveness of PH-specific agents on changing 6MWD results,\(^{14,24,28}\) and no between-group differences were found (MD, −2.16 meter; 95% CI, −8.00, 3.68; \( P = 0.47 \); \( I^2 = 22% \)) (Fig. 4C). Also, as shown in Fig. 4D, serious adverse events were similar between the study and control groups (RR, 0.97; 95% CI, 0.82, 1.15; \( P = 0.74 \); \( I^2 = 17% \)).\(^{24,25,27,28,30}\)

**DISCUSSION**

In this systematic review and meta-analysis, we report the following major findings. 1) The use of PH-specific agents did not improve all-cause mortality to end of study among IPF patients. Furthermore, although the included clinical trials showed a moderate degree of heterogeneity in populations and interventions, no clinical benefit in all-cause mortality to end of study was found in any of the sub-group analyses. 2) PH-specific agents yielded small benefits for patient quality of life, as estimated by SGRQ total score. 3) No association was observed between PH-specific agents and secondary outcomes (FVC decline, DLco decline, Borg dyspnea index score, and 6MWD decline). The number of serious adverse events did not differ significantly between the treatment and control groups.

PH is commonly observed to co-occur with IPF, and its presence is associated with a significant negative effect on survival time. In a large registry of 1,344 PH patients, 3-year survival was 44% for patients with PH-associated lung disease.\(^{32}\) Among an examined cohort, patients with established PH and interstitial lung disease had the worst 3-year survival rate of 16%.\(^{32}\) One-year mortality rates were higher in IPF patients with PH awaiting lung transplantation than in those without PH (28% vs. 5.5%, \( P = 0.002 \)).\(^{4}\) Targeted interventions against PH in IPF patients might be considered a feasible treatment option to improve clinical outcomes. PH-specific agents are regarded as experimental in IPF patients, and the use of these agents is not recommended by current guidelines because of pathophysiologic concerns and the lack of quality data.\(^ {3,33,34}\) However, PH-specific agents contribute to vasodilation and remodeling of the pulmonary vasculature, and some studies have reported that they are correlated with better clinical outcomes, including exercise capacity, symptoms, and quality of life.\(^ {14-16}\) To date, it has not been fully established whether PH-specific agents have a clinical effect on IPF patients.

Mortality to end of study is considered to be the most useful primary endpoint for Phase 3 clinical trials in IPF.\(^ {35}\) Mortality-related measures include all-cause mortality, respiratory-related mortality, and IPF-related mortality. Because all-cause mortality during follow-up is the cleanest and most easily interpreted mortality-related endpoint, we selected it as our primary endpoint.\(^ {35}\) In this study, we demonstrated that PH-specific agents were not associated with a reduction in all-cause mortality to end of study compared with controls. Although one RCT did report decreased all-cause mortality to end of study, its results were limited by a small sample size and high risk of bias.\(^ {26}\) The current findings of our pooled estimates might be explained in the following ways. 1) The development of IPF-associated PH can be explained by hypoxemia-induced vascular remodeling, IPF-specific hyperplasia and fibrosis of the elastic lamina of small pulmonary arteries, in situ thrombosis in small pulmonary arteries, intimal proliferation and fibrosis of the pulmonary venules, and various IPF-mediated cytokine effects.\(^ {36}\) Increased pulmonary vascular resistance could
result in fixed pulmonary vascular remodeling.37 Thus, PH-specific agents could provoke systemic hypotension if adequate cardiac output is not maintained, and they might not elicit pulmonary vasodilatation.37 2) PH-specific agents could attenuate the physiological hypoxic vasoconstrictor mechanism and increase blood flow to weakly ventilated lung areas. This could eventually lead to concerns about worsening the preexisting ventilation/perfusion mismatch and shunting, causing hypoxia.37

The clinical efficacy of PH-specific agents has been well established in patients with primary PH.34 It also has been proposed that PH-specific agents might benefit IPF patients with confirmed PH.15 However, little available research has focused on the clinical efficacy of PH-specific agents for IPF patients with confirmed PH; we could not conduct a meta-analysis of such studies due to insufficient data. Most of the studies that we excluded from our meta-analysis were non-randomized or were experimental trials focusing on short-term hemodynamic changes from baseline.37-42 We found three studies that examined treatment outcomes in IPF patients with confirmed PH.15,24,28 The first study examined the effects of ambrisentan on IPF progression and performed stratified analyses of patients with confirmed PH.28 The presence of baseline PH was not associated with a significant difference in IPF progression (HR, 2.42; 95% CI, 0.79, 7.38; P = 0.12 for ambrisentan vs. placebo).28 In the second RCT, which investigated the clinical efficacy of bosentan, no difference was found in invasive pulmonary hemodynamics, functional capacity, or symptoms between the bosentan and placebo groups at endpoint.24 Post hoc analysis revealed that sildenafil treatment resulted in better exercise capacity and quality of life than placebo in IPF patients with right ventricular systolic dysfunction.15

Parameters such as lung function, quality of life, dyspnea degree, and exercise capacity are commonly estimated in clinical trials evaluating the efficacy of treatments for IPF patients.43 Our pooled estimates indicate that PH-specific agents significantly affected quality of life, as measured by SGRQ total score. Additionally, although we identified two trials that examined quality of life, we had to exclude them from our pooled analyses because they used a scoring system other than the SGRQ or because they reported insufficient outcomes.16,27 The results of those trials were inconsistent with those of our pooled estimates. A large-scale RCT found no significant difference between the bosentan and control groups with regard to quality of life as measured by the 36-item Short-Form Health Survey and the EuroQol Group Five Dimension Self-Report questionnaire.27 Another exploratory study reported that bosentan treatment had a minimal effect on quality of life after 12 months and had beneficial effects on the SGRQ scores of the subset of IPF patients proven by surgical lung biopsy.16

To the best of our knowledge, this is the first meta-analysis to estimate the clinical impact of PH-specific agents compared with controls. However, our study has several limitations. First, because our meta-analysis was performed on a small number of trials, it might be insufficient to allow generalizations from our findings. Second, our results are based on findings from RCTs that used various PH-specific agents and a heterogeneous patient population. In particular, several studies allowed the use of concomitant medications, including anti-fibrotic agents and immunosuppressive agents.14,24-28 Those medications could have influenced our findings. Additionally, we could not find any RCTs that evaluated prostacyclin pathway agonists or sGCs among the classes of PH-specific agents available; the clinical effects of those agents should be more thoroughly investigated in the future. Third, the study duration ranged from 3 to 24 months of treatment with PH-specific agents, and a study duration of less than 6 months might be insufficient to characterize the clinical efficacy of treatment. Finally, because two trials reported findings extracted from the Sildenafil Trial of
Exercise Performance in IPF study, some patients were overlapped in the process of pooling the estimates,\textsuperscript{25,30} which could have elicited selection bias. We included both trials in the present study because they used differently defined populations.

In conclusion, our systematic review and meta-analysis reveals that there is insufficient evidence to suggest a clinical benefit of PH-specific agents among IPF patients, even though these agents provided a small benefit in terms of quality of life improvement. Our findings support the current international guidelines for IPF treatment, which recommend against administering PH-specific agents. Questions remain about whether PH-specific agents offer better outcomes for specific patient subgroups, such as IPF patients with confirmed PH.

**REFERENCES**

1. Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, et al. Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/RS/ALAT clinical practice guideline. *Am J Respir Crit Care Med* 2018;198(5):e44-68. [PUBMED](https://pubmed.ncbi.nlm.nih.gov/31622909/) | [CROSSREF](https://doi.org/10.1164/rccm.201707-1562OC)

2. Carlos WG, Strek ME, Wang TS, Patel H, Raghu G, Wilson KC, et al. Treatment of idiopathic pulmonary fibrosis. *Ann Am Thorac Soc* 2016;13(1):115-7. [PUBMED](https://pubmed.ncbi.nlm.nih.gov/26642417/) | [CROSSREF](https://doi.org/10.1513/Ann Thorac Soc.2015.08.0304)

3. Raghu G, Rochwerb B, Zhang Y, Garcia CA, Azuma A, Behr J, et al. An official ATS/ERS/RS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline. *Am J Respir Crit Care Med* 2015;192(2):e3-19. [PUBMED](https://pubmed.ncbi.nlm.nih.gov/25136004/) | [CROSSREF](https://doi.org/10.1164/rccm.201412-2181OC)

4. Lettieri CJ, Nathan SD, Barnett SD, Ahmad S, Shorr AF. Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. *Chest* 2006;129(3):746-52. [PUBMED](https://pubmed.ncbi.nlm.nih.gov/16748499/) | [CROSSREF](https://doi.org/10.1378/chest.129.3.746)

5. Nadrous HF, Pellikka PA, Krowka MJ, Swanson KL, Chaowalit N, Decker PA, et al. Pulmonary hypertension in patients with idiopathic pulmonary fibrosis. *Chest* 2005;128(4):2393-9. [PUBMED](https://pubmed.ncbi.nlm.nih.gov/15973680/) | [CROSSREF](https://doi.org/10.1378/chest.128.4.2393)

6. Nathan SD, Shlobin OA, Ahmad S, Urbanek S, Barnett SD. Pulmonary hypertension and pulmonary function testing in idiopathic pulmonary fibrosis. *Chest* 2007;131(3):657-63. [PUBMED](https://pubmed.ncbi.nlm.nih.gov/17540021/) | [CROSSREF](https://doi.org/10.1378/chest.131.3.657)

7. Shorr AF, Wainwright JL, Cors CS, Lettieri CJ, Nathan SD. Pulmonary hypertension in patients with pulmonary fibrosis awaiting lung transplant. *Eur Respir J* 2007;30(4):715-21. [PUBMED](https://pubmed.ncbi.nlm.nih.gov/17566044/) | [CROSSREF](https://doi.org/10.1183/09031936.07.00185006)

8. Nathan SD, Shlobin OA, Ahmad S, Koch J, Barnett SD, Ad N, et al. Serial development of pulmonary hypertension in patients with idiopathic pulmonary fibrosis. *Respiration* 2008;76(3):288-94. [PUBMED](https://pubmed.ncbi.nlm.nih.gov/19025432/) | [CROSSREF](https://doi.org/10.1159/000116237)

9. Papakosta D, Pitsiou G, Daniil Z, Dimadi M, Stagaki E, Rapti A, et al. Prevalence of pulmonary hypertension in patients with idiopathic pulmonary fibrosis: correlation with physiological parameters. *Lung* 2011;189(5):391-9. [PUBMED](https://pubmed.ncbi.nlm.nih.gov/21917003/) | [CROSSREF](https://doi.org/10.1007/s00408-011-0274-2)

10. Raghu G, Nathan SD, Behr J, Brown KK, Egan JJ, Kawut SM, et al. Pulmonary hypertension in idiopathic pulmonary fibrosis with mild-to-moderate restriction. *Eur Respir J* 2015;46(5):1370-7. [PUBMED](https://pubmed.ncbi.nlm.nih.gov/26148128/) | [CROSSREF](https://doi.org/10.1183/09031936.0021-2015)

11. Rivera-Lebron BN, Forfia PR, Kreider M, Lee JC, Holmes JH, Kawut SM. Echocardiographic and hemodynamic predictors of mortality in idiopathic pulmonary fibrosis. *Chest* 2013;144(2):564-70. [PUBMED](https://pubmed.ncbi.nlm.nih.gov/23519987/) | [CROSSREF](https://doi.org/10.1378/chest.12-2308)

12. Song JW, Song JK, Kim DS. Echocardiography and brain natriuretic peptide as prognostic indicators in idiopathic pulmonary fibrosis. *Respir Med* 2009;103(2):180-6. [PUBMED](https://pubmed.ncbi.nlm.nih.gov/19188497/) | [CROSSREF](https://doi.org/10.1016/j.resmed.2008.10.016)

13. Hamada K, Nagai S, Tanaka S, Handa T, Shigematsu M, Nagao T, et al. Significance of pulmonary arterial pressure and diffusion capacity of the lung as prognosticator in patients with idiopathic pulmonary fibrosis. *Chest* 2007;131(3):650-6. [PUBMED](https://pubmed.ncbi.nlm.nih.gov/17219286/) | [CROSSREF](https://doi.org/10.1378/chest.131.3.650)
14. King TE Jr, Behr J, Brown KK, du Bois RM, Lancaster L, de Andrade JA, et al. BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. *Am J Respir Crit Care Med* 2008;177(1):75-81. [PUBMED](https://pubmed.ncbi.nlm.nih.gov/) | [CROSSREF](https://doi.org/10.1164/rccm.200711-1699OR)

15. Han MK, Bach DS, Hagan PG, Yow E, Flaherty KR, Toews GB, et al. Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction. *Chest* 2013;143(6):1699-708. [PUBMED](https://pubmed.ncbi.nlm.nih.gov/) | [CROSSREF](https://doi.org/10.1378/chest.13-0377)

16. Raghu G, King TE Jr, Behr J, Brown KK, du Bois RM, Leconte I, et al. Quality of life and dyspnoea in patients treated with bosentan for idiopathic pulmonary fibrosis (BUILD-1). *Eur Respir J* 2010;35(1):118-23. [PUBMED](https://pubmed.ncbi.nlm.nih.gov/) | [CROSSREF](https://doi.org/10.1183/09031936.00064909)

17. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med* 2009;6(7):e1000097. [PUBMED](https://pubmed.ncbi.nlm.nih.gov/) | [CROSSREF](https://doi.org/10.1371/journal.pmed.1000097)

18. American Thoracic Society. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). *Am J Respir Crit Care Med* 2000;161(2 Pt 1):646-64. [PUBMED](https://pubmed.ncbi.nlm.nih.gov/) | [CROSSREF](https://doi.org/10.1164/0013058005028276)

19. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. *Am J Respir Crit Care Med* 2011;183(6):788-824. [PUBMED](https://pubmed.ncbi.nlm.nih.gov/) | [CROSSREF](https://doi.org/10.1164/rccm.201101-0063ST)

20. Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. *BMJ* 2011;343:d5928. [PUBMED](https://pubmed.ncbi.nlm.nih.gov/) | [CROSSREF](https://doi.org/10.1136/bmj.d5928)

21. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. *Biometrics* 1994;50(4):1088-101. [PUBMED](https://pubmed.ncbi.nlm.nih.gov/) | [CROSSREF](https://doi.org/10.2307/2533461)

22. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. *BMJ* 1997;315(7099):629-34. [PUBMED](https://pubmed.ncbi.nlm.nih.gov/) | [CROSSREF](https://doi.org/10.1136/bmj.315.7099.629)

23. Thompson SG. Why sources of heterogeneity in meta-analysis should be investigated. *BMJ* 1994;309(6965):1351-5. [PUBMED](https://pubmed.ncbi.nlm.nih.gov/) | [CROSSREF](https://doi.org/10.1136/bmj.309.6965.1351)

24. Corte TJ, Keir GJ, Dimopoulos K, Howard L, Corris PA, Parfitt L, et al. Bosentan in pulmonary hypertension associated with fibrotic idiopathic interstitial pneumonia. *Am J Respir Crit Care Med* 2014;190(2):208-17. [PUBMED](https://pubmed.ncbi.nlm.nih.gov/) | [CROSSREF](https://doi.org/10.1164/rccm.201306-1073OC)

25. Kolb M, Raghu G, Wells AU, Behr J, Richeldi L, Schinzel B, et al. Nintedanib plus sildenafil in patients with idiopathic pulmonary fibrosis. *N Engl J Med* 2018;379(18):1722-31. [PUBMED](https://pubmed.ncbi.nlm.nih.gov/) | [CROSSREF](https://doi.org/10.1056/NEJMoA1717405)

26. Tanaka Y, Hino M, Gemma A. Potential benefit of bosentan therapy in borderline or less severe pulmonary hypertension secondary to idiopathic pulmonary fibrosis-an interim analysis of results from a prospective, single-center, randomized, parallel-group study. *BMC Pulm Med* 2017;17(1):200. [PUBMED](https://pubmed.ncbi.nlm.nih.gov/) | [CROSSREF](https://doi.org/10.1186/s12890-017-0366-8)

27. King TE Jr, Brown KK, Raghu G, du Bois RM, Lynch DA, Martinez F, et al. BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. *Am J Respir Crit Care Med* 2011;184(1):92-9. [PUBMED](https://pubmed.ncbi.nlm.nih.gov/) | [CROSSREF](https://doi.org/10.1164/rccm.201102-0213OC)

28. Raghu G, Behr J, Brown KK, Egan JJ, Kawut SM, Flaherty KR, et al. Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial. *Ann Intern Med* 2013;158(9):641-9. [PUBMED](https://pubmed.ncbi.nlm.nih.gov/) | [CROSSREF](https://doi.org/10.7326/M13-0282)

29. Raghu G, Million-Rousseau R, Morganti A, Perchenet L, Behr JMUSIC Study Group. Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial. *Eur Respir J* 2013;42(6):1622-32. [PUBMED](https://pubmed.ncbi.nlm.nih.gov/) | [CROSSREF](https://doi.org/10.1183/09031936.00125212)

30. Idiopathic Pulmonary Fibrosis Clinical Research Network, Zisman DA, Schwarz M, Anstrom KJ, Collard HR, Flaherty KR, et al. A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. *N Engl J Med* 2010;363(7):620-8. [PUBMED](https://pubmed.ncbi.nlm.nih.gov/) | [CROSSREF](https://doi.org/10.1056/NEJMoa0908565)
31. Jackson RM, Glassberg MK, Ramos CF, Bejarano PA, Butrous G, Gómez-Marín O. Sildenafil therapy and exercise tolerance in idiopathic pulmonary fibrosis. *Lung* 2010;188(2):115-23.

32. Hurdman J, Condliffe R, Elliot CA, Davies C, Hill C, Wild JM, et al. ASPIRE registry: assessing the spectrum of pulmonary hypertension identified at a referral centre. *Eur Respir J* 2012;39(4):945-55.

33. Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). *Eur Heart J* 2016;37(1):67-119.

34. Galiè N, Corris PA, Frost A, Girgis RE, Granton J, Jing ZC, et al. Updated treatment algorithm of pulmonary arterial hypertension. *J Am Coll Cardiol* 2013;62(25 Suppl):D60-72.

35. Raghu G, Collard HR, Anstrom KJ, Flaherty KR, Fleming TR, King TE Jr, et al. Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials. *Am J Respir Crit Care Med* 2012;185(10):1044-8.

36. Patel NM, Lederer DJ, Borczuk AC, Kawut SM. Pulmonary hypertension in idiopathic pulmonary fibrosis. *Chest* 2007;132(3):998-1006.

37. Olschewski H, Ghofrani HA, Walmrath D, Schermuly R, Temmesfeld-Wollbruck B, Grimminger F, et al. Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis. *Am J Respir Crit Care Med* 1999;160(2):600-7.

38. Collard HR, Anstrom KJ, Schwarz MI, Zisman DA. Sildenafil improves walk distance in idiopathic pulmonary fibrosis. *Chest* 2007;131(3):897-9.

39. Madden BP, Allenby M, Loke TK, Sheth A. A potential role for sildenafil in the management of pulmonary hypertension in patients with parenchymal lung disease. *Vasc Pharmacol* 2006;44(5):372-6.

40. Minai OA, Sahoo D, Chapman JT, Mehta AC. Vaso-active therapy can improve 6-min walk distance in patients with pulmonary hypertension and fibrotic interstitial lung disease. *Respir Med* 2008;102(7):1015-20.

41. Olschewski H, Ghofrani HA, Walmrath D, Schermuly R, Temmesfeld-Wollbrück B, Grimminger F, et al. Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to pulmonary fibrosis. *Pneumologie* 2000;54(3):133-42.

42. Ghofrani HA, Wiedemann R, Rose F, Schermuly RT, Olschewski H, Weissmann N, et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. *Lancet* 2002;360(9337):895-900.

43. King TE Jr, Albera C, Bradford WZ, Costabel U, du Bois RM, Leff JA, et al. All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials. *Am J Respir Crit Care Med* 2014;189(7):825-31.